Search
Replay
PEDealReviewFinal PPT.ppt
Thursday, July 28, 2011
12 p.m. EST/9 a.m. PDT
One trillion dollars in uninvested capital is being reported from the sidelines of the deal economy. However, the deal race is heating up, and this capital is almost guaranteed to be used as private equity dealmakers look to grow through acquisitions. What does the post-recessionary environment mean for private equity dealmaking and will we ever see leveraged buyout volumes close to the $377 billion mark again?
On July 28, The Deal LLC will host a webcast to discuss the key takeaways from the 2011 Private Equity Buyer/Public M&A Deal Study conducted by Schulte Roth & Zabel LLP. This study focuses on the market practice for issues critical to dealmakers from some of the largest public deals involving private equity buyers.
Join The Deal's senior private equity writer David Carey; John Pollack, partner, SRZ; David Rosewater, partner, SRZ; and Howard D. Morgan, co-president, Castle Harlan Inc.; as they analyze and discuss the findings of this important private equity study and the trends and strategies that leaders are utilizing in today's private equity game.
Moderator: 
David Carey
Senior writer
The Deal LLC
David Carey has followed the buyout industry for more than 15 years. He is a
frequent guest on CNBC and is often quoted about private equity in the
general business press. He is the co-author of a book on Blackstone
Group and the private equity industry, King of Capital: The Remarkable Rise,
Fall, and Rise Again of Steve Schwarzman and Blackstone, published by Crown in 2010.
Expert panelists:
Howard D. Morgan
Co-president
Castle Harlan Inc.
Howard D. Morgan, co-president of Castle Harlan, joined Castle Harlan in 1996. From 2000 to 2002, he was executive director of CHAMP Private Equity, an affiliate of Castle Harlan in Sydney, Australia. He has been a director and executive committee member of CHAMP since its inception.
Previously, Morgan was a partner at The Ropart Group, a private equity investment firm, where he was particularly instrumental in the acquisitions and growth of Blyth Inc. and XTRA Corp.
Morgan began his career as an associate at Allen & Company Inc., working in mergers and acquisitions and private equity. He is a board member of CHAMP, IDQ, Pretium Packaging and Baker & Taylor. He is a former director of over one dozen companies, including UK-based Polypipe Global Holdings, Austar United Communications Ltd., AmeriCast technologies, Ciao Bella Gelato Company, Ion Track Instruments, Land 'N' Sea Distributing and Penrice Soda Products.
He is an officer of the Harvard Business School Alumni Association, chairman of the Harvard Business School Club of New York, and a director of the Alexander Hamilton Institute, the Parkinson's Disease Foundation and the World Press Institute and treasurer of the Friends of the Garvan Institute of Medical Research. Morgan received his B.A. from Hamilton College in mathematics and government and his M.B.A. from the Harvard Business School.
John M. Pollack
Partner
Schulte Roth & Zabel LLP
John M. Pollack, a partner in the New York office of Schulte Roth Zabel, practices in the areas of public and private mergers, acquisitions, divestitures, restructuring, recapitalizations, co-investments, tender and exchange offers, distressed transactions, and securities law matters generally. His clients include private investment funds, as well as U.S. and foreign publicly traded companies.
Pollack worked on the merger of DynCorp International Inc. with an affiliate of Cerberus Capital Management, L.P., a transaction which was selected by The Deal as one of 2010's "Private Equity Deals of the Year." He graduated magna cum laude from The George Washington University and The George Washington Law School, the latter bestowing upon him High Honors, Order of the Coif and an award for Highest Overall Proficiency in Securities Law.
David E. Rosewater
Partner
Schulte Roth & Zabel LLP
David E. Rosewater is a partner in the New York office, where his practice focuses on mergers & acquisitions, private equity/leveraged buyouts, distressed investments and acquisitions, and activist investing. Rosewater has represented numerous corporate and private equity buyers and sellers, including in connection with the acquisitions of Caritas Christi Health Care System, which was named 2010 "Deal of the Year" in the health care category by Investment Dealers' Digest magazine, Austrian bank BAWAG, integrated logistics systems services provider Syncreon, tabletop icon Lenox Group, GMAC, certain Newell Rubbermaid divisions and the factoring businesses of GE Capital and HSBC Business Credit. He has represented activist investors in connection with a number of major campaigns, including those involving CNET Networks, CSX Corp., Red Robin Gourmet Burgers Inc. and ASA Ltd.
Rosewater received his B.A., with distinction and high honors, from the University of Michigan and his J.D., cum laude, from New York University School of Law. 
Robert Landis
Partner
Riverside Co.
Robert Landis joined Riverside Co. in 2002 and is responsible for a team of 11 professionals that coordinates origination and structuring opportunities for investments. He has more than 40 years of financial services experience, including prior positions at Deutsche Banc Alex. Brown and Citibank. At Deutsche, he developed industry expertise in the consumer, industrial, transportation, aerospace and defense, and telecommunications sectors. At Citibank, he was vice president of the multinational group. Prior to that, Landis was a major in the U.S. Army. He holds a B.S. from the University of Colorado and an M.B.A in international management from the Garvin School of International Management.
